Paul Peter Tak
Director, Chief Executive Officer · 2 filings · Latest: Sep 10, 2026
Candel Therapeutics, Inc.
| Ticker | Owner | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Filing |
|---|---|---|---|---|---|---|---|---|---|
CADL | Paul Peter Tak | Director, Chief Executive Officer | Sep 11, 2026 | Sale | $10.46 | 59,379 | $620.9K | 113,321 | |
CADL | Paul Peter Tak | Director, Chief Executive Officer | Sep 10, 2026 | Sale | $11.50 | 220,866 | $2.5M | 172,700 | |
CADL | Paul Peter Tak | Director, Chief Executive Officer | Sep 10, 2026 | Option Exercise | $1.55 | 125,000 | $193.8K | 393,566 | |
CADL | PAUL PETER TAK | — | Sep 10, 2026 | Proposed Sale | $12.17 | 280,245 | $3.4M | — | |
CADL | PAUL PETER TAK | — | Mar 18, 2025 | Proposed Sale | $8.83 | 74,106 | $654.4K | — | |
CADL | Tak Paul Peter | — | Jan 15, 2025 | Proposed Sale | $7.84 | 19,970 | $156.6K | — | |
CADL | Tak Paul Peter | — | Jan 8, 2025 | Proposed Sale | $8.35 | 20,811 | $173.8K | — | |
CADL | Tak Paul Peter | — | Nov 29, 2024 | Proposed Sale | $4.95 | 44,433 | $219.9K | — |